Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Eli Lilly and Incyte announced that the European Medicines Agency's CHMP has issued a positive opinion for baricitinib (OLUMIANT®) to treat moderate to severe atopic dermatitis (AD) in adults. This marks a significant step towards regulatory approval in Europe, potentially making it the first JAK inhibitor approved for AD. The opinion is based on the Phase 3 BREEZE-AD clinical trials which demonstrated efficacy and safety. A final decision from the European Commission is expected within two months, highlighting the urgency for more treatment options for patients suffering from AD.
Eli Lilly and Incyte announced promising results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which involved over 1,000 hospitalized patients. The trial assessed the efficacy of baricitinib combined with remdesivir, showing a significant reduction of approximately one day in median recovery time compared to remdesivir alone. This finding is statistically significant and meets the primary endpoint of the study. Lilly intends to seek emergency use authorization for the 4-mg dose of baricitinib for COVID-19 treatment, while also continuing trials to understand its full potential.